APTOF
Aptose Biosciences Inc.Company Information
- Company Name
- Aptose Biosciences Inc.
- CIK
- CIK0000882361
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- APTOF: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- APTOF
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-25
- Last sale
- —
- Shares purchased (TTM)
- 100,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 24,179
- Shares outstanding
- 2,552,429
- Ownership
- 0.95%
Earnings Market Reaction
- Filing date
- 2026-05-13
- Price on filing date
- —
- 1-month reaction
- -7.65%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | - | 1 | 1 | 1 | 5 | 6 | 8 | 8 | 7 | 9 | 16 | 8 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | 2 | - | 2 | 15 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | 3 | 1 | - | - | 1 | - | - | - | - | - | - | ||||||
| Restricted Cash Equivalents Current | - | 3 | - | 1 | - | 1 | - | - | - | 0 | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 6 | 6 | 4 | 3 | 7 | 10 | 10 | 10 | 12 | 12 | 20 | 25 | ||||||
| Cash | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Restricted Cash | 3 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | 5 | 4 | 3 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 4 | 3 | 2 | 2 | - | 0 | - | - | - | - | - | - | ||||||
| Assets | 11 | 10 | 6 | 6 | 7 | 10 | 11 | 11 | 13 | 13 | 21 | 27 | ||||||
| Accounts Payable Current | 4 | 3 | 1 | 3 | 2 | 1 | 2 | 7 | 2 | 3 | 3 | 4 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 7 | 6 | 5 | 5 | 3 | 3 | 8 | 5 | 9 | 9 | 9 | 8 | ||||||
| Liabilities Current | 11 | 9 | 7 | 9 | 6 | 4 | 10 | 13 | 12 | 15 | 12 | 12 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 34 | 28 | 19 | 11 | 9 | 10 | 10 | - | - | 1 | - | - | ||||||
| Operating Lease Liability Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 45 | 37 | 26 | 20 | 15 | 15 | 20 | 13 | 13 | 16 | 13 | 13 | ||||||
| Common Stock Value | 460 | 460 | 460 | 460 | 460 | 457 | 452 | 452 | 450 | 445 | 444 | 439 | ||||||
| Additional Paid In Capital | 84 | 84 | 84 | 84 | 84 | 83 | 82 | 82 | 79 | 72 | 72 | 71 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -35 | -27 | -19 | -14 | -7 | -5 | -9 | -2 | 0 | -3 | 8 | 14 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -4 | ||||||
| Retained Earnings Accumulated Deficit | -574 | -566 | -559 | -554 | -547 | -541 | -539 | -532 | -525 | -516 | -504 | -492 | ||||||
| Liabilities And Stockholders Equity | 11 | 10 | 6 | 6 | 7 | 10 | 11 | 11 | 13 | 13 | 21 | 27 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAptose Biosciences Inc. (APTOF) — SEC Financial Statements & Analysis
Aptose Biosciences Inc. (APTOF) is a biological products, (no diagnostic substances) company, incorporated in A6. Aptose Biosciences Inc. trades on OTC as: APTOF. Aptose Biosciences Inc. (APTOF)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-13. Based on that filing, On profitability, Aptose Biosciences Inc. posts a Return on Equity (ROE) of 131.03%, a Return on Assets (ROA) of -303.01%, and a Return on Invested Capital (ROIC) of -456.60%. Per share, it reports EPS of $-10.80, diluted EPS of $-10.80, free cash flow per share of $-9.81, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 29.18% year-over-year and EPS growth of 7.62% year-over-year. On the balance sheet, it maintains a current ratio of 0.55x, a quick ratio of 0.38x, working capital of $-5.08M, a debt-to-equity ratio of -1.31x, a debt ratio of 4.23, an interest coverage ratio of -84.59x, free cash flow of $-25.04M (TTM), and net debt of $-1.02M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-10.80
- ROE TTM
- 131.03%
- ROA TTM
- -303.01%
- Debt To Equity
- -1.31x
- Free Cash Flow TTM
- $-25.04M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aptose Biosciences Inc. in?
Aptose Biosciences Inc. (APTOF) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does APTOF trade on?
Aptose Biosciences Inc. (APTOF) trades on the OTC.
Where is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Ontario, Canada.
When was Aptose Biosciences Inc. (APTOF)'s most recent SEC filing?
Aptose Biosciences Inc. (APTOF)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-13.
What is APTOF's EPS (earnings per share)?
Aptose Biosciences Inc. (APTOF)'s trailing twelve month EPS is $-10.80 as of 2026-03-31.
What is APTOF's ROE (return on equity)?
Aptose Biosciences Inc. (APTOF)'s trailing twelve month Return on Equity (ROE) is 131.03% as of 2026-03-31.
What is APTOF's ROA (return on assets)?
Aptose Biosciences Inc. (APTOF)'s trailing twelve month Return on Assets (ROA) is -303.01% as of 2026-03-31.
What is APTOF's ROIC (return on invested capital)?
Aptose Biosciences Inc. (APTOF)'s trailing twelve month Return on Invested Capital (ROIC) is -456.60% as of 2023-06-30.